Effects of Cyclosporine on Reperfusion Injury in Patients: A Meta-Analysis of Randomized Controlled Trials

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Song, Kangxing ^a   Wang, Shuxia ^a   Qi, Dake ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CARDIOLOGY; ENZYMES;

ACUTE MYOCARDIAL INFARCTION; ELECTRONIC DATABASE; LEFT VENTRICULAR EJECTION FRACTION; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; STANDARDIZED ALGORITHMS;

DRUG PRODUCTS;

CREATINE KINASE; CREATINE KINASE MB; CYCLOSPORIN A; TROPONIN I; CARRIER PROTEIN; CYCLOSPORIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE;

ALGORITHM; ARTICLE; DRUG EFFECT; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; META ANALYSIS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; DIAGNOSTIC IMAGING; DRUG EFFECTS; FACTUAL DATABASE; HEART LEFT VENTRICLE FUNCTION; HUMAN; METABOLISM; MYOCARDIAL REPERFUSION INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY;

ANIMALIA;

CREATINE KINASE; CREATINE KINASE, MB FORM; CYCLOSPORINE; DATABASES, FACTUAL; HUMANS; MAGNETIC RESONANCE IMAGING; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TROPONIN I; VENTRICULAR FUNCTION, LEFT;

EID: 84934282213     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/287058     Document Type: Article

References (32)

1. C. D. Mathers and D. Loncar, "Projections of global mortality and burden of disease from 2002 to 2030", PLoS Medicine, vol. 3, no. 11, article e442, 2006.
2. J. L. Anderson, C. D. Adams, E. M. Antman et al., "2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines", Circulation, vol. 127, no. 23, pp. e663-e828, 2013.
3. L. Gomez, B. Li, N. Mewton et al., "Inhibition of mitochondrial permeability transition pore opening: translation to patients", Cardiovascular Research, vol. 83, no. 2, pp. 226-233, 2009.
4. E. Braunwald and R. A. Kloner, "Myocardial reperfusion: a double-edged sword?" The Journal of Clinical Investigation, vol. 76, no. 5, pp. 1713-1719, 1985.
5. D. Garcia-Dorado, A. Rodríguez-Sinovas, M. Ruiz-Meana, and J. Inserte, "Protection against myocardial ischemia-reperfusion injury in clinical practice", Revista Espanola de Cardiologia, vol. 67, no. 5, pp. 394-404, 2014.
6. X. Ma, H. Liu, S. R. Foyil et al., "Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury", Circulation, vol. 125, no. 25, pp. 3170-3181, 2012.
7. S. Gao, H. Li, X. Feng et al., "α-enolase plays a catalytically independent role in doxorubicin-induced cardiomyocyte apoptosis and mitochondrial dysfunction", Journal of Molecular and Cellular Cardiology, vol. 79, pp. 92-103, 2015.
8. A. P. Halestrap and A. P. Richardson, "The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury", Journal of Molecular and Cellular Cardiology, vol. 78, pp. 129-141, 2015.
9. F. Di Lisa, N. Kaludercic, A. Carpi, R. Menabò, and M. Giorgio, "Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66Shc and monoamine oxidase", Basic Research in Cardiology, vol. 104, no. 2, pp. 131-139, 2009.
10. P. Z. Gerczuk and R. A. Kloner, "An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials", Journal of the American College of Cardiology, vol. 59, no. 11, pp. 969-978, 2012.
11. W. Y. Lim, C. M. Messow, and C. Berry, "Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis", British Journal of Pharmacology, vol. 165, no. 7, pp. 2034-2043, 2012.
12. C. Piot, P. Croisille, P. Staat et al., "Effect of cyclosporine on reperfusion injury in acute myocardial infarction", The New England Journal of Medicine, vol. 359, no. 5, pp. 473-481, 2008.
13. S. Ghaffari, B. Kazemi, M. Toluey, and N. Sepehrvand, "The Effect of prethrombolytic cyclosporine-a injection on clinical outcome of acute anterior st-elevation myocardial infarction", Cardiovascular Therapeutics, vol. 31, no. 4, pp. e34-e39, 2013.
14. D. Moher, B. Pham, A. Jones et al., "Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?" The Lancet, vol. 352, no. 9128, pp. 609-613, 1998.
15. R. Der Simonian and N. Laird, "Meta-analysis in clinical trials", Controlled Clinical Trials, vol. 7, no. 3, pp. 177-188, 1986.
16. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, "Measuring inconsistency in meta-analyses", British Medical Journal, vol. 327, no. 7414, pp. 557-560, 2003.
17. S. Morota, T. Manolopoulos, A. Eyjolfsson et al.", Functional and pharmacological characteristics of permeability transition in isolated human heart mitochondria", PLoS ONE, vol. 8, no. 6, Article ID e67747, 2013.
18. E. Pahl, S. A. Miller, B. P. Griffith, and F. J. Fricker, "Occult restrictive hemodynamics after pediatric heart transplantation", The Journal of Heart and Lung Transplantation, vol. 14, pp. 1109-1115, 1995.
19. L. A. Vricella, J. M. Karamichalis, S. Ahmad, R. C. Robbins, R. I. Whyte, and B. A. Reitz, "Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the Stanford experience", Annals of Thoracic Surgery, vol. 74, no. 1, pp. 13-18, 2002.
20. N. Mewton, P. Croisille, G. Gahide et al., "Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction", Journal of the American College of Cardiology, vol. 55, no. 12, pp. 1200-1205, 2010.
21. P. Chiari, D. Angoulvant, N. Mewton et al., "Cyclosporine protects the heart during aortic valve surgery", Anesthesiology, vol. 121, no. 2, pp. 232-238, 2014.
22. D. J. Hausenloy, G. Kunst, E. Boston-Griffiths et al., "The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial", Heart, vol. 100, no. 7, pp. 544-549, 2014.
23. R. S. Gill, D. L. Bigam, and P.-Y. Cheung, "The role of cyclosporine in the treatment ofmyocardial reperfusion injury", Shock (Augusta, Ga), vol. 37, no. 4, pp. 341-347, 2012.
24. A. P. Halestrap, S. J. Clarke, and S. A. Javadov, "Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection", Cardiovascular Research, vol. 61, no. 3, pp. 372-385, 2004.
25. Q. Cai, G. F. Baxter, and D. M. Yellon, "Reduction of infarct size in isolated rat heart by Cs A and FK506: possible role of phosphatase inhibition", Cardiovascular Drugs and Therapy, vol. 12, no. 5, pp. 499-501, 1998.
26. J. Li, A. Iorga, S. Sharma et al., "Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A", Anesthesiology, vol. 117, no. 4, pp. 836-846, 2012.
27. J. Zhu, M. J. Rebecchi, Q. Wang, P. S. A. Glass, P. R. Brink, and L. Liu, "Chronic Tempol treatment restores pharmacological preconditioning in the senescent rat heart", The American Journal of Physiology-Heart and Circulatory Physiology, vol. 304, no. 5, pp. H649-H659, 2013.
28. R. J. Burns, R. J. Gibbons, Q. Yi et al., "The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis", Journal of the American College of Cardiology, vol. 39, no. 1, pp. 30-36, 2002.
29. N. Krestnikova, A. Stulpinas, A. Imbrasaite, G. Sinkeviciute, and A. V. Kalvelyte, "JNK implication in adipocyte-like cell death induced by chemotherapeutic drug cisplatin", The Journal of Toxicological Sciences, vol. 40, no. 1, pp. 21-32, 2015.
30. S. Wang, H. He, L. Chen, W. Zhang, X. Zhang, and J. Chen, "Protective effects of salidroside in the MPTP/MPP+-induced model of parkinson's disease through ros-no-related mitochondrion pathway", Molecular Neurobiology, 2014.
31. V. Appierto, P. Tiberio, M. G. Villani, E. Cavadini, and F. Formelli, "PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation", Carcinogenesis, vol. 30, no. 5, pp. 824-831, 2009.
32. R. Der Simonian and R. Kacker, "Random-effects model for meta-analysis of clinical trials: an update", Contemporary Clinical Trials, vol. 28, no. 2, pp. 105-114, 2007.